SUNSHINE PHARMA (06887) News

Selected Hong Kong Stock Announcements | HaiZhi Technology Partners with ZhiPu AI for Strategic Collaboration; Green Tea Group Reports Over 30% Year-on-Year Increase in Annual Profit

① What are the highlights of the strategic cooperation between Haizhi Technology and Zhipu? ② Green Tea Group's annual profit increased by more than 30% year-on-year. What is the scale?

cls.cnFeb 24 19:56

Guolian Minsheng Securities: Small Nucleic Acids Reshape Weight Loss Logic; INHBE and ALK7 Targets Preliminarily Validated

Small nucleic acids and GLP-1 drugs exhibit synergistic effects, with major weight loss companies already investing in small nucleic acid drugs. GLP-1 controls intake, while small nucleic acids regulate metabolism, making them a potential 'golden combination' in the field of weight management.

Zhitong FinanceFeb 12 14:27

Stock Movement | Dongyang Pharmaceutical (06887) rose over 4% in early trading after the company announced a significant strategic cooperation agreement with XtalPi Holdings.

Dongyangguang Pharmaceutical (06887) rose over 4% in early trading. As of the time of writing, it was up 4.06%, trading at HKD 46.68 with a turnover of HKD 13.8169 million.

Zhitong FinanceJan 27 11:00

Hong Kong Stock Announcements | Dongpeng Beverages begins its IPO subscription today. Joyson Electronic expects an increase of approximately 40.56% in annual net profit attributable to shareholders.

Zijin Gold International proposes to acquire 100% of Allied Gold Corporation for approximately CAD 5.5 billion.

Zhitong FinanceJan 26 23:05

Dongyang Sunshine Pharmaceutical (06887) has entered into a strategic cooperation agreement with Shenzhen XtalPi to establish a joint venture and jointly build an AI-driven drug discovery platform.

Dongyang Sunshine Pharmaceutical (06887) announced that on January 26, 2026, the company entered into a strategic cooperation agreement with Shenzhen XtalPi Technology Co., Ltd. (Shenzhen XtalPi). Under the strategic cooperation agreement, the two parties plan to establish a joint venture to build an AI-driven drug discovery platform, focusing on the following areas of cooperation:

Zhitong FinanceJan 26 19:11

Stock Movement | Dongyangguang Medicine (06887) surged over 6% in the afternoon after its Class 1 new drug, Ologliflozin, was approved for marketing. The company recently launched an AI-powered intelligent R&D platform.

Dongyangguang Pharmaceutical (06887) surged over 6% in the afternoon trading session. As of the time of writing, it was up 6.55%, trading at HKD 46.2 with a turnover of HKD 30.6289 million.

Zhitong FinanceJan 22 14:06

Sunshine Lake Pharma Gets China Nod for Marketing of Glycemic Control Drug

MT NewswiresJan 16 20:27

Hong Kong Stock Announcements | Wuxi XDC Makes a Cash Offer for TOT Biopharm-B at a Premium of Approximately 99%; Trading Resumes on January 15

CITIC Securities (06030) reported a net profit attributable to shareholders of 30.051 billion yuan for the fiscal year 2025, representing a year-on-year increase of 38.46%. Wuxi XDC (02268) announced an expected year-on-year growth of over 38% in net profit for the fiscal year 2025.

Zhitong FinanceJan 14 23:05

Dongyang Sunshine Pharmaceutical (06887.HK): Launches a globally leading PROTAC mechanism AI-powered R&D platform.

Gelonghui, January 14th丨Dongyangguang Pharmaceutical (06887.HK) announced that the group continues to deepen its AI strategic layout by launching an AI intelligent R&D platform targeting the PROTAC mechanism. This platform achieves a "dry-wet closed loop" from the data foundation, with data scale and structural granularity significantly surpassing existing public databases. It provides comprehensive and systematic data support for AI-driven rational design of PROTACs, accelerating the rational design and clinical translation of PROTAC lead compounds. Traditional small-molecule drugs rely on clearly defined binding pockets of target proteins, while 80% of human disease-related proteins are considered "undruggable" due to the lack of suitable structural characteristics.

Gelonghui FinanceJan 14 21:14

Zhitong HK Stock Short Position Statistics | January 9

Zhitong HK Stock Short Position Report | January 9

Zhitong FinanceJan 9 18:30

Share Repurchase Roundup on January 6 | Companies such as Tencent and Xiaomi Group-W conducted share repurchases, with Tencent spending HKD 636 million.

According to a disclosure document issued by the Hong Kong Exchange on January 7, companies such as Tencent and Xiaomi Group-W repurchased shares. ① On January 6, Tencent repurchased 1.003 million ordinary shares for an amount of HKD 636 million at a price per share ranging from HKD 638 to HKD 626.5. Since the resolution authorizing the repurchase, the total number of securities repurchased has reached 105 million shares, accounting for 1.143% of the issued share capital at the time of the passing of the ordinary resolution. ② Xiaomi Group-W

Futu NewsJan 7 09:20

Dongyang Guangyao (06887.HK) repurchased 9,900 shares at a cost of HKD 428,000 on January 6.

Gelonghui, January 6th: Dongyangguang Pharmaceutical (06887.HK) announced that it repurchased 9,900 shares at a cost of HKD 428,000 on January 6th.

Gelonghui FinanceJan 6 18:42

Share Repurchase Summary on January 5 | Companies such as Tencent and Xiaomi Group-W conducted share buybacks, with Tencent spending HKD 636 million.

According to a disclosure document released by the Hong Kong Exchange on January 6, companies such as Tencent and Xiaomi Group-W (01810.HK) repurchased shares. ① Tencent repurchased 1.018 million ordinary shares on January 5 at a total cost of HKD 636 million, with the repurchase price per share ranging from HKD 627.5 to HKD 617. Since the resolution authorizing the repurchase, the cumulative number of securities repurchased has reached 104 million shares, representing 1.132% of the total number of issued shares at the time the ordinary resolution was passed. ② Xiaomi Group-W (01810.HK)

Futu NewsJan 6 09:10

Hong Kong Stock Announcements | Seres reports total December vehicle sales of 63,700 units, a year-on-year increase of 53.54%.

Seres' total vehicle sales in December reached 63,700 units, marking a year-on-year increase of 53.54%; the 'Shanhai‧Zhiyi Large Model' empowered Unisound to secure a regional medical cooperation contract worth over 20 million yuan.

Zhitong FinanceJan 5 22:50

Sunshine Lake Pharma Enrolls First Patient in Hepatitis B Virus-Targeting Drug

MT NewswiresJan 5 21:18

Hong Kong Stock Announcements Highlights | Chifeng Gold Expects Annual Profit to Exceed 3 Billion Yuan, Xindong Company Proposes Share Repurchase Worth 400 Million Hong Kong Dollars

① Chifeng Gold forecasts annual profits to exceed 3 billion yuan. How fast is the year-on-year growth rate? ② XD Company plans to repurchase shares worth 400 million Hong Kong dollars. How long is the trading window?

cls.cnJan 5 20:41

Dongyang Guangyao (06887) repurchased 88,800 shares for HKD 3.8983 million on January 5.

Dongyang Guangyao (06887) announced that on January 5, 2026, the company repurchased 88,800 shares at a total cost of 3.8983 million Hong Kong dollars, with the repurchase price ranging from HKD 43.22 to HKD 44.90 per share.

Zhitong FinanceJan 5 20:37

Dongyang Guangyao (06887.HK): Small nucleic acid drug gains international recognition, with clinical and technology platforms advancing in tandem.

Gelonghui, January 5th丨Dongyangguang Pharmaceutical (06887.HK) announced that HECN30227 is a Class 1 innovative drug independently developed by the group with global intellectual property rights. It can simultaneously eliminate hepatitis B surface antigen (HBsAg) derived from cccDNA and intDNA. Preclinical data shows that HECN30227 exhibits pan-genotypic activity, effectively reducing HBsAg levels. It maintains significant efficacy against nucleoside drug-resistant strains and demonstrates superior in vivo and in vitro efficacy compared to competing clinical products. HECN30227 utilizes the group's uniquely designed HEC-GalNova (N-acetylgalactosamine).

Gelonghui FinanceJan 5 19:14

Share Repurchase Roundup on January 2 | Companies such as Tencent and ShouCheng Holdings conducted share buybacks, with Tencent spending HKD 636 million.

According to a disclosure document released by the Hong Kong Exchange on January 5, companies including Tencent and ShouCheng Holdings repurchased shares. ① Tencent repurchased 1.029 million ordinary shares on January 2 at a total cost of HKD 636 million, with the repurchase price ranging between HKD 624 and HKD 600.5 per share. Since the resolution authorizing share repurchases, the cumulative number of securities repurchased has reached 103 million shares, representing 1.121% of the total issued shares at the time of the passing of the ordinary resolution. ② ShouCheng Holdings also conducted repurchases on January 2.

Futu NewsJan 5 09:30

Dongyang Sunshine Pharmaceutical (06887) repurchased 49,100 shares on January 2 at a cost of HKD 2.192 million.

Dongyangguang Pharmaceutical (06887) announced that on January 2, 2026, it repurchased 49,100 shares at a cost of HKD 2.192 million.

Zhitong FinanceJan 2 18:42